E-grāmata: Regulatory T cells and Autoimmune Diseases

Part I Regulatory T cells and immune system
1. Regulatory T cells and their functions in immune system
2. Regulatory T cells: mechanisms of action
3. Regulatory T cells and autoimmunity
4. Sex differences in regulatory T cells during autoimmune disease

Part II Role of regulatory T cells in rheumatic diseases
5. Role of regulatory T cells in pathogenesis and therapeutics of systemic
lupus erythematosus
6. Role of regulatory T cells in the pathogenesis and therapeutics of primary
Sjögrens syndrome
7. Role of regulatory T cells in pathogenesis and therapeutics of rheumatoid
arthritis and juvenile idiopathic arthritis
8. Role of regulatory T cells in pathogenesis and therapeutics of psoriatic
arthritis
9. Role of regulatory T cells in pathogenesis and therapeutics of
spondyloarthritis
10. Role of regulatory T cells in pathogenesis and therapeutics of ankylosing
spondylitis

Part III Role of regulatory T cells in central nervous system demyelinating
autoimmune diseases
11. Role of regulatory T cells in pathogenesis and therapeutics of multiple
sclerosis
12. Role of regulatory T cells in the pathogenesis and therapeutics of
neuromyelitis optica spectrum disorder

Part IV Role of regulatory T cells in peripheral nerve, muscle and
neuromuscular autoimmune diseases
13. Role of regulatory T cells in pathogenesis and therapeutics of myasthenia
gravis
14. Role of regulatory T cells in pathogenesis and therapeutics of
GuillainBarré syndrome and experimental autoimmune neuritis
15. Role of regulatory T cells in pathogenesis and therapeutics of chronic
inflammatory demyelinating polyradiculoneuropathy
16. Role of regulatory T cells in pathogenesis and therapeutics of
dermatomyositis and polymyositis

Part V Role of regulatory T cells in inflammatory bowel diseases
17. Role of regulatory T cells in pathogenesis and therapeutics of Crohns
disease and ulcerative colitis
18. Role of regulatory T cells in pathogenesis and therapeutics of celiac
disease

Part VI Role of regulatory T cells in autoimmune liver diseases
19. Role of regulatory T cells in the pathogenesis and therapeutics of
autoimmune hepatitis
20. Role of regulatory T cells in pathogenesis and therapeutics of primary
biliary cholangitis and primary sclerosing cholangitis

Part VII Role of regulatory T cells in autoimmune thyroid diseases
21. Role of regulatory T cells in pathogenesis and therapeutics of
Hashimotos thyroiditis
22. Role of regulatory T cells in pathogenesis and therapeutics of Graves
disease and Graves orbitopathy

Part VIII Role of regulatory T cells in autoimmune lung and kidney diseases
23. Role of regulatory T cells in pathogenesis and therapeutics of
Goodpastures syndrome (anti-glomerular basement membrane disease)
24. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune
glomerulonephritis (IgA vasculitis and IgA nephropathy)

Part IX Role of regulatory T cells in autoimmune skin diseases
25. Role of regulatory T cells in pathogenesis and therapeutics of vitiligo
26. Role of regulatory T cells in pathogenesis and therapeutics of psoriasis
27. Role of regulatory T cells in pathogenesis and therapeutics of atopic
dermatitis
28. Role of regulatory T cells in pathogenesis and therapeutics of alopecia
areata
29. Role of regulatory T cells in pathogenesis and therapeutics of pemphigus
vulgaris and bullous pemphigoid
30. Role of regulatory T cells in pathogenesis and therapeutics of
scleroderma (systemic sclerosis)

Part X Role of regulatory T cells in autoimmune blood and blood vessel
disorders
31. Role of regulatory T cells in pathogenesis and therapeutics of primary
antiphospholipid syndrome (Hughes syndrome)
32. Role of regulatory T cells in pathogenesis and therapeutics of Kawasaki
disease
33. Role of regulatory T cells in pathogenesis and therapeutics of Behēet
disease
34. Role of regulatory T cells in pathogenesis and therapeutics of immune
thrombocytopenia
35. Role of regulatory T cells in pathogenesis and treatment of
antineutrophil cytoplasmic antibody-associated vasculitis
36. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune
hemolytic anemia

Part XI Role of regulatory T cells in autoimmune eye diseases and type 1
diabetes mellitus
37. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune
uveitis
38. Role of regulatory T cells in pathogenesis and therapeutics of autoimmune
retinopathy
39. Role of regulatory T cell in pathogenesis and therapeutics of type 1
diabetes mellitus

Part XII Current challenges and future prospects in research towards
regulatory T cells based therapeutics in autoimmune diseases
40. Vaccines induced effects on functioning of regulatory T cells: autoimmune
perspective
41. Probiotic interventions for regulatory T cells induction in autoimmune
diseases
42. CAR Treg-based therapeutics for autoimmune diseases
43. Current challenges and future prospects of regulatory T cells based
therapeutics in autoimmune disease

Mitesh Kumar Dwivedi, PhD, is an assistant professor of microbiology at the C. G. Bhakta Institute of Biotechnology, Uka Tarsadia University. He has published 63 research papers and 46 book chapters, edited 8 books, and serves as an editorial board member and reviewer of many international journals. He has an h-index of 25 with 2261 citations for his research papers. His research interests include investigation of immunogenetic, autoimmune, and therapeutic aspects of vitiligo, rheumatoid arthritis, sickle cell disease, and the role of probiotics in amelioration of autoimmune diseases. He is a recipient of numerous honors: DST-SERB Core Research Grant (2022), SERB-SIRE International Research Fellowship (2022), Best Researcher Award (2020), INSA Visiting Scientist Award (2019), DST-SERB Early Career Research Award (2018), Young Scientist Awards (2011, 2013, and 2018), and all India rank 32” in CSIR-NET national examination (2011; Life Sciences). He has successfully completed six research projects as principal investigator from national funding agencies: SERB-DST, GUJCOST, UTU, and Neo Sciences & Research Solutions Pvt. Ltd. and guided students for their doctoral and master degrees.

DeLisa Fairweather, PhD, is a professor of medicine and immunology and director of translational research in the Department of Cardiovascular Medicine at Mayo Clinic in Jacksonville, Florida, studying sex/gender differences in cardiovascular and autoimmune diseases, including myocarditis. Her research has been continuously funded by the National Institutes of Health (NIH), the American Heart Association (AHA), BARDA, and others. She serves on NIH, the Board of the Atwal Clinic and Mayo Clinic Mitochondrial Research Center, and formerly on the Board of the Myocarditis Foundation. She was a leader of the US FDA Mayo-led Expanded Access Program during the COVID-19 pandemic. She has served on the National Academies of Sciences, Engineering, and Medicine (NASEM) committee making recommendations to NIH and Congress on the autoimmune disease portfolio of NIH and on the NASEM committee to examine side effects of COVID-19 vaccines. She is a member of the Scientific Advisory Board for the Autoimmune Registry as well as the Organization for the Study of Sex Differences (OSSD).